Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple

Executive Summary

FDA’s review of novel efficacy endpoints for diabetes therapies inevitably included discussion of the future of the cardiovascular outcomes study requirement for type 2 diabetes therapies; comments by FDA and EMA officials sure make it sound like the requirement isn’t going away any time soon.

Advertisement

Related Content

US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs
FDA Commissioner Candidate Gulfo Hates Breakthrough, Wants To Reevaluate User Fees
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Diabetes Treatment Shift Coming? Cleveland Clinic’s Nissen Declares Victory
Diabetes Trials Tend To Eschew Patient-Reported Outcomes
Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome
Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel